Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …

Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative
and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

Background In an interim analysis of this phase 3 trial, the addition of pembrolizumab to
chemotherapy resulted in longer progression-free survival than chemotherapy alone among …

Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor
(HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …

Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-dependent
kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase …

Background Patients who have residual invasive carcinoma after the receipt of neoadjuvant
chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative breast …

Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC)
include anthracycline-cyclophosphamide and taxane-based chemotherapy. …